Compare UUU & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UUU | MBRX |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 9.6M |
| IPO Year | 2025 | 2016 |
| Metric | UUU | MBRX |
|---|---|---|
| Price | $3.50 | $0.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | 10.4K | ★ 1.7M |
| Earning Date | 02-19-2026 | 05-12-2026 |
| Dividend Yield | ★ 16.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,847,163.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.86 | $0.16 |
| 52 Week High | $8.27 | $7.98 |
| Indicator | UUU | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 16.60 |
| Support Level | $3.02 | $0.35 |
| Resistance Level | $4.13 | $0.57 |
| Average True Range (ATR) | 0.30 | 0.22 |
| MACD | 0.07 | -0.17 |
| Stochastic Oscillator | 50.25 | 10.65 |
Universal Safety Products Inc designs and markets a variety of popularly priced safety products which, consisted mainly of smoke alarms, carbon monoxide alarms and related products. Its products require minimal installation and are designed for easy installation by the consumer without professional assistance and are sold through retail stores. It also market products to the electrical distribution trade. The electrical distribution trade includes electrical and lighting distributors as well as manufactured housing companies. Products it sell usually require professional installation. Its products are 2-in-1 Smoke & Fire Alarms, 3-in-1 Combo Alarms, and CO Alarms.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.